Louie Pasculli, Assistant Editor for NeurologyLive®, has been with the team since October 2025. Follow him on X @Louie_Pasculli or email him at lpasculli@neurologylive.com
A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.
Pediatrics specialists discussed approaches to assessing depressive symptoms that may overlook key risk factors, highlighting the need for improved self-report measures, developmentally appropriate tools, and more precise symptom characterization. [WATCH TIME: 3 MINUTES]
Pediatrics specialists discussed key methodological limitations of a recently published study, including variability across sites, reliance on caregiver-report measures, and the lack of developmentally appropriate tools for assessing depression in youth with intellectual disabilities. [WATCH TIME: 4 MINUTES]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC)!
Pediatric specialists reflected on the challenges and gaps in assessing depressive and anxiety symptoms among youth with epilepsy, emphasizing that patients with lower IQs are often excluded from research and clinical screening. [WATCH TIME: 3 MINUTES]
Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.
Pediatric specialists reflected on the goal and findings of the study, describing the elevated prevalence of depressive symptoms among youth with epilepsy and highlighting temporal lobe epilepsy as a particularly high-risk subgroup. [WATCH TIME: 2 MINUTES]
A trio of clinician authors provided insights on a recently published paper assessing youths with refractory epilepsy and ways to combat depressive symptoms.
The European Commission approved Biogen’s high-dose nusinersen regimen for 5q SMA, supported by DEVOTE trial data showing significantly improved motor function with a safety profile consistent with the standard-dose regimen.
Annette Langer-Gould, MD, PhD, lead for clinical and translational neuroscience at Kaiser Permanente, discusses findings and significance from a recently published trial assessing rituximab in patients with relapsing multiple sclerosis.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Annexon submitted an EMA marketing application for tanruprubart, a first-in-class C1q monoclonal antibody that showed faster and more complete recovery in Guillain-Barré syndrome patients across randomized trials.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy comorbidities!
A review of clinical trial and real-world data found no evidence that oral anticoagulants increase brain imaging abnormalities in patients treated with lecanemab or donanemab for early Alzheimer disease.
In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.
The director of the EEG/Epilepsy Unit in the Department of Clinical Neurosciences at Lausanne University Hospital in Switzerland discussed post-anoxic seizure management at 2025 AES Annual Meeting. [WATCH TIME: 3 minutes]
Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.
The Baldwin Keyes Professor of Neurology at the Sidney Kimmel Medical College at Thomas Jefferson University and Founder’s Award recipient discussed the state of the epilepsy care community and his outlook for the future. [WATCH TIME: 4 minutes]
A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.
Benjamin Greenberg, MD, MHS, a nationally recognized neuroimmunologist, spoke about the clinical impact of the latest NMOSD recommendations and their implications for diagnosis and care.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on preventative migraine therapies!
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!
A neuroscientist associated with the Cleveland Clinic Epilepsy Center discussed the rapid expansion and excitement surrounding the continued integration of AI in the field of epilepsy care. [WATCH TIME: 5 minutes]
Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.
At AES 2025, a clinical neuropsychologist at the Cleveland Clinic Epilepsy Center discussed the growing challenges facing older adults with epilepsy and the need for more comprehensive, research-informed care strategies. [WATCH TIME: 4 minutes]
Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!
Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.
New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.
